文献速递术前评估与围术期医学

氟哌啶醇与昂丹司琼治疗全麻后已确立恶心呕吐的随机临床试验

Haloperidol Versus Ondansetron for Treatment of Established Nausea and Vomiting Following General Anesthesia: A Randomized Clinical Trial.
PubMed 文献 · Anesth Analg · 2017-01-01

氟哌啶醇在早期和0-24小时完全缓解率上非劣于昂丹司琼,但镇静发生率显著更高(25% vs 2%,P<.001)。

要点

  • 氟哌啶醇1mg治疗已确立PONV的4小时完全缓解率非劣于昂丹司琼4mg。
  • 氟哌啶醇组镇静发生率为25%,显著高于昂丹司琼组的2%。
  • 两组疼痛、满意度、镇痛需求及QTc间期变化无差异。

核心结论

  • 氟哌啶醇对已确立PONV的早期治疗非劣于昂丹司琼,但伴有更多镇静。

研究设计与样本

  • 主要终点为术后4小时内无PONV,最终分析112例(氟哌啶醇组59例,昂丹司琼组53例)。

主要发现

  • 符合方案分析中,早期完全缓解率氟哌啶醇组59%(35/59)对昂丹司琼组55%(29/53),差异5%(95%CI -13%至22%)。
  • 符合方案分析中,0-24小时完全缓解率氟哌啶醇组53%(31/59)对昂丹司琼组49%(26/53),差异4%(95%CI -15%至21%)。
  • 意向性分析中,早期完全缓解率氟哌啶醇组58%(35/60)对昂丹司琼组48%(29/60),差异10%(95%CI -8%至27%)。
  • 意向性分析中,0-24小时完全缓解率氟哌啶醇组52%(31/60)对昂丹司琼组43%(26/60),差异8%(95%CI -9%至25%)。
  • 氟哌啶醇组25%患者出现镇静,昂丹司琼组2%(P<.001;差异23%;95%CI 11%-36%)。

关键数值与推荐

  • 非劣效界值为15%。
  • 氟哌啶醇组52%患者术前接受1或2种预防性止吐药,昂丹司琼组为79%。

临床怎么用

  • 氟哌啶醇1mg可作为昂丹司琼4mg的替代方案用于全麻后已确立PONV的早期治疗。
  • 使用氟哌啶醇时需考虑其较高的镇静风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Haloperidol is an antipsychotic. At low doses, it is a useful agent for the prophylaxis of postoperative nausea and vomiting (PONV). However, its use for treating established PONV has not been well studied. METHODS: This randomized double-blinded trial tested whether haloperidol is noninferior to ondansetron for the early treatment of established PONV in adult patients undergoing general anesthesia. The primary outcome is whether patients were PONV free during the first 4 hours. The noninferiority margin was set at 15%. One hundred twenty patients with PONV received either haloperidol 1 mg intravenously (n = 60) or ondansetron 4 mg intravenously (n = 60). RESULTS: Data from 112 patients (59 in the haloperidol group and 53 in the ondansetron group) were analyzed. Thirty-five patients (52%) in the haloperidol group received 1 or 2 prophylactic antiemetics compared with 42 (79%) in the ondansetron group. Haloperidol was noninferior to ondansetron for the end point of complete response to treatment (defined as the rate of PONV-free patients) for the early (0-4 hour) and the 0- to 24-hour postoperative periods by both the per-protocol and intention-to-treat analyses. In the per-protocol analysis, complete responses in the early period were noted in 35 of 59 patients (59%) and 29 of 53 patients (55%) for the haloperidol and ondansetron groups, respectively (difference 5%; 95% confidence interval [CI]: -13% to 22 %), and in the 0- to 24-hour period in 31 of 59 patients (53%) and 26 of 53 patients (49%) for the haloperidol and ondansetron groups, respectively (difference 4%; 95% CI of the difference: -15% to 21%). In the intention-to-treat analysis, complete responses in the early period were noted in 35 of 60 patients (58%) and 29 of 60 patients (48%) for the haloperidol and ondansetron groups, respectively (difference 10%; 95% CI of difference: -8% to 27%) and in the 0- to 24-hour period in 31 of 60 patients (52%) and 26 of 60 patients (43%) for the haloperidol and ondansetron groups, respectively (difference 8%; 95% CI of the difference: -9% to 25%). All other PONV secondary outcomes were comparable. Twenty-five percent of patients in the haloperidol group were sedated versus 2% in the ondansetron group (P < .001; difference 23%; 95% CI of the difference: 11%-36%). Pain, satisfaction scores, need for analgesics, and changes in QTc intervals were not different between the 2 groups. CONCLUSIONS: Haloperidol is at worst 13% and 8% less effective than ondansetron by per-protocol analysis and by intention-to-treat analysis, respectively. Thus, it is noninferior to ondansetron for the early treatment of established PONV, but is associated with sedation.

来源:Anesth Analg,查看原文。版权归原作者所有。

引用

  1. Yazbeck-Karam VG, Siddik-Sayyid SM, Barakat HB, et al. Haloperidol Versus Ondansetron for Treatment of Established Nausea and Vomiting Following General Anesthesia: A Randomized Clinical Trial. Anesth Analg. 2017. PMID: 28002167. doi:10.1213/ANE.0000000000001723

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。